Expression der Cyclooxygenase-2 im MammakarzinomBerit Maria Müller 3 Widmung4161.11.1.171.1.21.281.39101.4529#431111.51213141.61.6.11.6.2151.716622#466171.82182.1192.2202.2.12.2.221222.2.32.2.4232425262.2.5272.2.6282.3292.3.12.3.2302.3.3312.3.42.3.5322.3.62.3.7332.3.82.3.93343.13.2353.33.3.13637383.3.23940444#268446#27041532#290481#29042491#285491#28543511#296481#27944481#290491#2853.4453.4.146535#361535#35847522#379522#374483.4.2535#40249535#3733.4.350535#38751535#38452533.554563.6343#170356#170573.7271#216270#216270#21558270#216270#216270#21659259#207259#207259#2074604.16162634.2644.365664.4674.568694.670 Abkürzungsverzeichnis5Literaturverzeichnis727374757677 Persönliche Angaben78Tabellarischer Lebenslauf Erklärung an Eides Statt79 Danksagung8081PublikationsverzeichnisEigene KongressbeiträgedeInhaltsverzeichnisHilfe Literaturverzeichnis [1] Stabenow R, Eisinger B (2001): Epidemiologische Daten zum weiblichen Brustkrebs aus dem Gemeinsamen Krebsregister der Länder Berlin, Brandenburg, Mecklenburg-Vorpommern, Sachsen-Anhalt und der Freistaaten Sachsen und Thüringen. Schriftenreihe des GKR 1/ 2001: 40 [2]Jemal A, Thomas A, Murray T, Thun M (2002): Cancer Statistics, 2002. CA Cancer J Clin 52: 23-47 [3]Kreienberg R, Volm T, Alt D (2002): Krankheitsbild: Mammakarzinom. In: Kreienberg R, Volm T, Möbus V, Alt D (Hrsg.): Management des Mammakarzinoms. 2. Auflage. Springer- Verlag,

Berlin Heidelberg New York

, 3-6 [4]Riede UN, Wittekind C, Sterry W (1999): Epidermodermales System. In: Riede UN, Schaefer HE (Hrsg.): Allgemeine und spezielle Pathologie. 4. Auflage. Thieme

. Stuttgart New York

, 954-961 [5]Arun B, Hortobagyi GN (2002): Progress in breast cancer chemoprevention. Endocr Relat Cancer 9: 15-32 [6]Preiß J, Dornoff W, Hagmann FG, Schmieder A (2002): Onkologie 2002/ 2003, Empfehlungen zur Therapie. 11. Auflage . W. Zuckerschwerdt Verlag GmbH, 127-146 [7]Balkwill F, Mantovani A (2001): Inflammation and cancer: back to Virchow?. Lancet 357: 539-545 [8]Dvorak HF (1986): Tumors: wounds that do not heal. N Engl J Med 315: 1650-1659 [9]Hauptmann S (2000): Die Rolle der Entzündung bei der Tumorinvasion. Verh. Dtsch. Ges. Path. 84: 77-86 [10]Vane JR (1971): Inhibition of prostaglandin synthesis as a mechanism of action for Aspirin-like drugs. Nat New Biol 231: 232-235 [11]Vane JR, Flower RJ, Botting RM (1990): History of Aspirin and its mechanism of action. Stroke 21 (4): IV12-23 [12]Taketo MM (1998): Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst. 90 (20): 1529-1536 [13]Stack E, DuBois RN (2001): Regulation of cyclo-oxygenase-2. Best Pract Res Clin Gastroenterol 15 (5): 787-800 [14]Hla T, Bishop- Bailey D, Liu CH, Schaefers HJ, Trifan OC (1999): Cyclooxygenase-1 and –2 isoenzymes. Int J Biochem Cell Biol 31 : 551-557 [15]Howe LR, Subbaramaiah K, Brown AMC, Dannenberg AJ (2001): Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8: 97-114 [16]Taketo MM (1998): Cyclooygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst. 90 (21): 1609-1620 [17]Cannon GW, Breedveld FC (2001): Efficacy of Cyclooxygenase- 2- specific inhibitors. Am J Med 110 (3A): 6S-12S [18]Brune K, Kalden J, Zacher J, Zeilhofer HU (2000): Selektive Inhibitoren der Zykooxygenase 2. Deutsches Ärzteblatt 97 (26): A-1818-A1825 [19]Phillips RKS, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su L-K, Sherman J, Kelloff G, Levin B, Steinbach G, the FAP Study Group (2002): A randomised, double blind, placebo controled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 50 (6): 857-860 [20]Khuder SA, Mutgi AB (2001): Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84 (9): 1188-1192 [21]Johnson TW, Anderson KE, Lazovich DA, Folsom AR (2002): Association of Aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 11: 1586-1591 [22]Elston CW, Ellis IO (1991): Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 5: 403-410 [23]Sobin LJ, Wittekind L (2002): TNM classification of malignant tumors. Wiley-Liss, 6. ed. [24]Remmele W, Stegner HE (1987): Recommendation for uniform definition of an immunoreactive score (IRS) for immunhistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140 [25]Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA (2002): Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62: 1676-1681 [26]Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J (2002): Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer . Cancer Res 62 : 632-635 [27]Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF (2001): Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res 61: 4375-4381 [28]Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N (2000): Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients . Clin. Cancer Res 6: 4064-4068 [29]Newton R, Kuitert LME, Bergmann M, Adcock IM, Barnes PJ (1997): Evidence for involvement of NF- κ B in the transcriptional control of COX-2 gene expression by IL-1 β . Biochem Biophys Res Commun (237): 28-32 [30]Denkert C, Winzer KJ, Muller BM, Weichert W, Pest S, Kobel M, Kristiansen G, Reles A, Siegert A, Guski H, Hauptmann S. (2003): Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survivall and overall survivall in patients with breast carcinoma. Cancer 97 (12): 2978-2987 [31]Soslow RA, Dannenberg AJ, Rudh D, Woerner BM, Khan KN, Masferrer J, Koki AT (2000): COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89 (12): 2637-2645 [32]Costa C, Soares R, Reis-Filho JS, Leitão D, Amendoeira I, Schmitt FC (2002): Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55: 429-434 [33]Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, Amberger A, Margreiter R, Obrist P (2003): Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer (88): 574-578 [34]Davies G, Salter J, Hills M, Martin L-A, Sacks N, Dowsett M (2003): Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin. Cancer Res 9: 2651-2656 [35]Lim SC (2003) : Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma. Oncol Rep. 10 (5): 1241-1249 [36]Wülfing P, Diallo R, Müller C, Wülfing C, Poremba C, Heinecke A, Rody A, Greb RR, Böcker W, Kiesel L (2003): Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 129: 375-382 [37]Denkert C, Köbel M, Pest S, Koch I, Berger S, Schwabe M, Siegert A, Reles A, Klosterhalfen B, Hauptmann S (2002): Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160: 893-903 [38]Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N (2000): Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 6 (10): 4064-4068 [39]Shono T, Tofilon PJ, Brunner JM, Owolabi O, Lang FF (2001): Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 61: 4375-4381 [40]Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA (2000): The cyclooxygenase-2 inhibitor Celecoxib is a potent preventive and therapeutic agent in the Min Mouse Model of adenomatous polyposis. Cancer Res (60): 5040-5044 [41]Harris RE, Alshafie GA, Abou-Issa H, Seibert K (2000): Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60: 2101-2103 [42]Liu XH, Rose DP (1996): Differential expression and regulation of cyclooygenase-1 and –2 in two human breast cancer cell lines. Cancer Res 56: 5152-5127 [43]Parente L, Perretti M (2003): Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol 65: 153-159 [44]Huang M, Sharma S, Mao JT, Dubinett SM (1996): Non-small lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 157 (12): 5512-5520 [45]Tsujii M, DuBois RN (1995): Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83 (3): 493-501 [46]DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD (1996): G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 56 (4): 733-737 [47]Tsujii M, Kawano S, DuBois RN (1997): Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340 [48]Takahashi Y, Kawahara F, Noguchi M, Miwa K, Sato H, Seiki M, Inoue H, Tanabe T, Yoshimoto T (1999): Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or –2. FEBS Lett 460 (1): 145-148 [49]Lim SC, Park SY, Do NY (2003): Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma. Oncol Rep. 10 (5): 1073-1079 [50]Chu J, Lloyd FL, Trifan OC, Knapp B, Rizzo MT (2003): Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther (1): 1-7 [51]Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998): Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 94 (2): following 271 [52]Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN (2000): Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105: 1589-1594 [53]Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ (1999): Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis . Cancer Res 59: 4574-4577 [54]Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawaski AS (1999): Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 12 (5): 1418-1423 [55]Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN (1998): Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58 (2): 362-366 [56]Rigas B, Shiff SJ (2000): Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction . Med Hypotheses 54 (2): 210-221